nach oben

Reviews in Endocrine and Metabolic Disorders

Erschienen in:

30.03.2021

Imaging of neuroendocrine tumors: A pictorial review of the clinical value of different imaging modalities

verfasst von: Ali Pirasteh, Petra Lovrec, Lisa Bodei

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Neuroendocrine tumors (NETs) are multifaceted tumors occurring in a variety of organs and often present as metastatic at the time of diagnosis. Accurate staging is the most significant factor in therapy planning, but it remains a challenge. Imaging is established as the cornerstone for disease detection/diagnosis, staging, and follow up. To accurately assess and monitor tumor burden in patients with NETs, various imaging techniques have been developed and optimized. Current recommendations for the imaging of patients with NETs include a combination of both morphologic (or anatomic) and molecular imaging, but a final choice can be puzzling for clinicians. Recognizing that there is no uniform sequence consensus on the “best” imaging test, and the heterogeneity of technologic availability at different centers, we hope to provide a pictorial review of the different imaging techniques and their role and utility in management of patients with NETs, aimed to provide a practical guide for all clinicians.

Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer. 1997;79(4):813–29.CrossRefPubMed

Ter-Minassian M, Chan JA, Hooshmand SM, Brais LK, Daskalova A, Heafield R, et al. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocr Relat Cancer. 2013;20(2):187–96. https://doi.org/10.1530/ERC-12-0340.CrossRefPubMedPubMedCentral

Pape UF, Berndt U, Muller-Nordhorn J, Bohmig M, Roll S, Koch M, et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2008;15(4):1083–97. https://doi.org/10.1677/ERC-08-0017.CrossRefPubMed

Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B, Modlin IM. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40(1):111–34, viii. https://doi.org/10.1016/j.ecl.2010.12.001.

Marotta V, Zatelli MC, Sciammarella C, Ambrosio MR, Bondanelli M, Colao A, et al. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. Endocr Relat Cancer. 2018;25(1):R11–29. https://doi.org/10.1530/ERC-17-0269.CrossRefPubMed

Kidd M, Bodei L, Modlin IM. Chromogranin A: any relevance in neuroendocrine tumors? Curr Opin Endocrinol Diabetes Obes. 2016;23(1):28–37. https://doi.org/10.1097/med.0000000000000215.CrossRefPubMed

Corti A, Marcucci F, Bachetti T. Circulating chromogranin A and its fragments as diagnostic and prognostic disease markers. Pflugers Arch. 2018;470(1):199–210. https://doi.org/10.1007/s00424-017-2030-y.CrossRefPubMed

Modlin IM, Kidd M, Malczewska A, Drozdov I, Bodei L, Matar S, et al. The NETest: The Clinical Utility of Multigene Blood Analysis in the Diagnosis and Management of Neuroendocrine Tumors. Endocrinol Metab Clin North Am. 2018;47(3):485–504. https://doi.org/10.1016/j.ecl.2018.05.002.CrossRefPubMedPubMedCentral

Malczewska A, Procner A, Walter A, Kusnierz K, Zajecki W, Aslanian H, et al. The NETest liquid biopsy is diagnostic for gastric neuroendocrine tumors: observations on the blood-based identification of microscopic and macroscopic residual diseaseOK. BMC Gastroenterol. 2020;20(1):235. https://doi.org/10.1186/s12876-020-01348-2.CrossRefPubMedPubMedCentral

10.

Bodei L, Kidd MS, Singh A, van der Zwan WA, Severi S, Drozdov IA, et al. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest. Eur J Nucl Med Mol Imaging. 2020;47(4):895–906. https://doi.org/10.1007/s00259-019-04601-3.CrossRefPubMed

11.

Ruf J, Schiefer J, Furth C, Kosiek O, Kropf S, Heuck F, et al. 68Ga-DOTATOC PET/CT of Neuroendocrine Tumors: Spotlight on the CT Phases of a Triple-Phase Protocol. J Nucl Med. 2011;52(5):697–704. https://doi.org/10.2967/jnumed.110.083741.CrossRefPubMed

12.

Park HJ, Kim HJ, Kim KW, Kim SY, Choi SH, You M-W, et al. Comparison between neuroendocrine carcinomas and well-differentiated neuroendocrine tumors of the pancreas using dynamic enhanced CT. Eur Radiol. 2020. https://doi.org/10.1007/s00330-020-06867-w.CrossRefPubMed

13.

Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, et al. The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the north American neuroendocrine tumor society. Pancreas. 2017;46(6):715–31. https://doi.org/10.1097/MPA.0000000000000846.CrossRefPubMedPubMedCentral

14.

Sundin A. Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012;26(6):803–18. https://doi.org/10.1016/j.bpg.2012.12.004.CrossRefPubMed

15.

Kamaoui I, De-Luca V, Ficarelli S, Mennesson N, Lombard-Bohas C, Pilleul F. Value of CT enteroclysis in suspected small-bowel carcinoid tumors. Am J Roentgenol. 2010;194(3):629–33. https://doi.org/10.2214/AJR.09.2760.CrossRef

16.

Paulsen SR, Huprich JE, Fletcher JG, Booya F, Young BM, Fidler JL et al. CT enterography as a diagnostic tool in evaluating small bowel disorders: review of clinical experience with over 700 cases. Radiographics. 2006;26(3):641–57; discussion 57–62. https://doi.org/10.1148/rg.263055162.

17.

Hakim FA, Alexander JA, Huprich JE, Grover M, Enders FT. CT-Enterography may identify small bowel tumors not detected by capsule endoscopy: eight years experience at mayo clinic rochester. Dig Dis Sci. 2011;56(10):2914–9. https://doi.org/10.1007/s10620-011-1773-0.CrossRefPubMed

18.

Huprich JE, Fletcher JG, Fidler JL, Alexander JA, Guimarães LS, Siddiki HA, et al. Prospective blinded comparison of wireless capsule endoscopy and multiphase CT enterography in obscure gastrointestinal bleeding. Radiology. 2011;260(3):744–51. https://doi.org/10.1148/radiol.11110143.CrossRefPubMed

19.

Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103(2):153–71. https://doi.org/10.1159/000443171.CrossRefPubMed

20.

Power SP, Moloney F, Twomey M, James K, O’Connor OJ, Maher MM. Computed tomography and patient risk: Facts, perceptions and uncertainties. World J Radiol. 2016;8(12):902–15. https://doi.org/10.4329/wjr.v8.i12.902.CrossRefPubMedPubMedCentral

21.

Mahesh M, Morin RL. CT scans and cancer risks-a practical middle path. J Am Coll Radiol. 2016;13(7):828–30. https://doi.org/10.1016/j.jacr.2016.04.008.CrossRefPubMed

22.

Costello JE, Cecava ND, Tucker JE, Bau JL. CT radiation dose: current controversies and dose reduction strategies. AJR Am J Roentgenol. 2013;201(6):1283–90. https://doi.org/10.2214/ajr.12.9720.CrossRefPubMed

23.

Böning G, Kahn JF, Kaul D, Rotzinger R, Freyhardt P, Pavel M, et al. CT follow-up in patients with neuroendocrine tumors (NETs): combined radiation and contrast dose reduction. Acta Radiol. 2018;59(5):517–26. https://doi.org/10.1177/0284185117726101.CrossRefPubMed

24.

Zinsser D, Marcus R, Othman AE, Bamberg F, Nikolaou K, Flohr T, et al. Dose reduction and dose management in computed tomography - state of the art. Rofo. 2018;190(6):531–41. https://doi.org/10.1055/s-0044-101261.CrossRefPubMed

25.

Kubo T. Vendor free basics of radiation dose reduction techniques for CT. Eur J Radiol. 2019;110:14–21. https://doi.org/10.1016/j.ejrad.2018.11.002.CrossRefPubMed

26.

Davenport MS, Perazella MA, Yee J, Dillman JR, Fine D, McDonald RJ, et al. Use of intravenous iodinated contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation. Radiology. 2020;294(3):660–8. https://doi.org/10.1148/radiol.2019192094.CrossRefPubMed

27.

Malagò R, D’Onofrio M, Zamboni GA, Faccioli N, Falconi M, Boninsegna L, et al. Contrast-enhanced sonography of nonfunctioning pancreatic neuroendocrine tumors. AJR Am J Roentgenol. 2009;192(2):424–30. https://doi.org/10.2214/ajr.07.4043.CrossRefPubMed

28.

D’Onofrio M, Mansueto G, Falconi M, Procacci C. Neuroendocrine pancreatic tumor: value of contrast enhanced ultrasonography. Abdom Imaging. 2004;29(2):246–58. https://doi.org/10.1007/s00261-003-0097-8.CrossRefPubMed

29.

Serra C, Felicani C, Mazzotta E, Piscitelli L, Cipollini ML, Tomassetti P, et al. Contrast-enhanced ultrasound in the differential diagnosis of exocrine versus neuroendocrine pancreatic tumors. Pancreas. 2013;42(5):871–7. https://doi.org/10.1097/MPA.0b013e31827a7b01.CrossRefPubMed

30.

Del Prete M, Di Sarno A, Modica R, Lassandro F, Giorgio A, Bianco A, et al. Role of contrast-enhanced ultrasound to define prognosis and predict response to biotherapy in pancreatic neuroendocrine tumors. J Endocrinol Invest. 2017;40(12):1373–80. https://doi.org/10.1007/s40618-017-0723-x.CrossRefPubMed

31.

van Asselt SJ, Brouwers AH, van Dullemen HM, van der Jagt EJ, Bongaerts AH, Kema IP et al. EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1. Gastrointest Endosc. 2015;81(1):159–67 e2. https://doi.org/10.1016/j.gie.2014.09.037.

32.

James PD, Tsolakis AV, Zhang M, Belletrutti PJ, Mohamed R, Roberts DJ et al. Incremental benefit of preoperative EUS for the detection of pancreatic neuroendocrine tumors: a meta-analysis. Gastrointest Endosc. 2015;81(4):848–56 e1. https://doi.org/10.1016/j.gie.2014.12.031.

33.

Anderson MA, Carpenter S, Thompson NW, Nostrant TT, Elta GH, Scheiman JM. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol. 2000;95(9):2271–7. https://doi.org/10.1111/j.1572-0241.2000.02480.x.CrossRefPubMed

34.

Dromain C, de Baere T, Lumbroso J, Caillet H, Laplanche A, Boige V, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol. 2005;23(1):70–8. https://doi.org/10.1200/JCO.2005.01.013.CrossRefPubMed

35.

Hope TA, Pampaloni MH, Nakakura E, VanBrocklin H, Slater J, Jivan S, et al. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdom Imaging. 2015;40(6):1432–40. https://doi.org/10.1007/s00261-015-0409-9.CrossRefPubMed

36.

Berzaczy D, Giraudo C, Haug AR, Raderer M, Senn D, Karanikas G, et al. Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors: A Prospective Study in 28 Patients. Clin Nucl Med. 2017;42(9):669–74. https://doi.org/10.1097/RLU.0000000000001753.CrossRefPubMedPubMedCentral

37.

Schreiter NF, Nogami M, Steffen I, Pape UF, Hamm B, Brenner W, et al. Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours. Eur Radiol. 2012;22(2):458–67. https://doi.org/10.1007/s00330-011-2266-4.CrossRefPubMed

38.

Schraml C, Schwenzer NF, Sperling O, Aschoff P, Lichy MP, Muller M, et al. Staging of neuroendocrine tumours: comparison of [68Ga]DOTATOC multiphase PET/CT and whole-body MRI. Cancer Imaging. 2013;13(1):63–72. https://doi.org/10.1102/1470-7330.2013.0007.CrossRefPubMedPubMedCentral

39.

Farchione A, Rufini V, Brizi MG, Iacovazzo D, Larghi A, Massara RM, et al. Evaluation of the added value of diffusion-weighted imaging to conventional magnetic resonance imaging in pancreatic neuroendocrine tumors and comparison with 68Ga-DOTANOC positron emission tomography/computed tomography. Pancreas. 2016;45(3):345–54. https://doi.org/10.1097/mpa.0000000000000461.CrossRefPubMed

40.

d’Assignies G, Fina P, Bruno O, Vullierme MP, Tubach F, Paradis V, et al. High sensitivity of diffusion-weighted MR imaging for the detection of liver metastases from neuroendocrine tumors: comparison with T2-weighted and dynamic gadolinium-enhanced MR imaging. Radiology. 2013;268(2):390–9. https://doi.org/10.1148/radiol.13121628.CrossRefPubMed

41.

Moryoussef F, de Mestier L, Belkebir M, Deguelte-Lardiere S, Brixi H, Kianmanesh R, et al. Impact of liver and whole-body diffusion-weighted MRI for neuroendocrine tumors on patient management: a pilot study. Neuroendocrinology. 2017;104(3):264–72. https://doi.org/10.1159/000446369.CrossRefPubMed

42.

Sankowski AJ, Cwikla JB, Nowicki ML, Chaberek S, Pech M, Lewczuk A et al. The clinical value of MRI using single-shot echoplanar DWI to identify liver involvement in patients with advanced gastroenteropancreatic-neuroendocrine tumors (GEP-NETs), compared to FSE T2 and FFE T1 weighted image after i.v. Gd-EOB-DTPA contrast enhancement. Med Sci Monit. 2012;18(5):MT33–40. https://doi.org/10.12659/msm.882719.

43.

Ichikawa T, Peterson MS, Federle MP, Baron RL, Haradome H, Kawamori Y, et al. Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. Radiology. 2000;216(1):163–71. https://doi.org/10.1148/radiology.216.1.r00jl26163.CrossRefPubMed

44.

Thoeni RF, Mueller-Lisse UG, Chan R, Do NK, Shyn PB. Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. Radiology. 2000;214(2):483–90. https://doi.org/10.1148/radiology.214.2.r00fe32483.CrossRefPubMed

45.

Lee L, Ito T, Jensen RT. Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies. Expert Rev Anticancer Ther. 2018;18(9):837–60. https://doi.org/10.1080/14737140.2018.1496822.CrossRefPubMedPubMedCentral

46.

Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27(3):273–82.CrossRefPubMed

47.

Kabasakal L, Demirci E, Ocak M, Decristoforo C, Araman A, Ozsoy Y, et al. Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39(8):1271–7. https://doi.org/10.1007/s00259-012-2123-y.CrossRefPubMed

48.

Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, et al. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med. 2018;59(1):66–74. https://doi.org/10.2967/jnumed.117.202275.CrossRefPubMedPubMedCentral

49.

Walker RC, Smith GT, Liu E, Moore B, Clanton J, Stabin M. Measured Human Dosimetry of 68Ga-DOTATATE. J Nucl Med. 2013;54(6):855–60. https://doi.org/10.2967/jnumed.112.114165.CrossRefPubMed

50.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16. https://doi.org/10.1093/jnci/92.3.205.

51.

Schwartz LH, Seymour L, Litiere S, Ford R, Gwyther S, Mandrekar S et al. RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. Eur J Cancer. 2016;62:138–45. https://doi.org/10.1016/j.ejca.2016.03.082.

52.

Geijer H, Breimer LH. Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2013;40(11):1770–80. https://doi.org/10.1007/s00259-013-2482-z.CrossRefPubMed

53.

Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, et al. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. J Clin Oncol. 2016;34(6):588–96. https://doi.org/10.1200/JCO.2015.64.0987.CrossRefPubMed

54.

Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, et al. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. J Nucl Med. 2016;57(5):708–14. https://doi.org/10.2967/jnumed.115.163865.CrossRefPubMed

55.

Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48(4):508–18. https://doi.org/10.2967/jnumed.106.035667.CrossRefPubMed

56.

Skoura E, Michopoulou S, Mohmaduvesh M, Panagiotidis E, Al Harbi M, Toumpanakis C, et al. The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom. J Nucl Med. 2016;57(1):34–40. https://doi.org/10.2967/jnumed.115.166017.CrossRefPubMed

57.

Barrio M, Czernin J, Fanti S, Ambrosini V, Binse I, Du L, et al. The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis. J Nucl Med. 2017;58(5):756–61. https://doi.org/10.2967/jnumed.116.185587.CrossRefPubMed

58.

Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, et al. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors. J Nucl Med. 2013;54(3):364–72. https://doi.org/10.2967/jnumed.112.111724.CrossRefPubMed

59.

Carideo L, Prosperi D, Panzuto F, Magi L, Pratesi MS, Rinzivillo M, et al. Role of Combined [68Ga]Ga-DOTA-SST Analogues and [18F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review. J Clin Med. 2019;8(7):1032. https://doi.org/10.3390/jcm8071032.CrossRefPubMedCentral

60.

Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors. Clin Cancer Res. 2010;16(3):978–85. https://doi.org/10.1158/1078-0432.ccr-09-1759.CrossRefPubMed

61.

Sansovini M, Severi S, Ianniello A, Nicolini S, Fantini L, Mezzenga E, et al. Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE. Eur J Nucl Med Mol Imaging. 2017;44(3):490–9. https://doi.org/10.1007/s00259-016-3533-z.CrossRefPubMed

62.

Hofman MS, Hicks RJ. Changing paradigms with molecular imaging of neuroendocrine tumors. Discov Med. 2012;14(74):71–81.PubMed

63.

Hindie E. The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors. Theranostics. 2017;7(5):1159–63. https://doi.org/10.7150/thno.19588.CrossRefPubMedPubMedCentral

64.

Severi S, Nanni O, Bodei L, Sansovini M, Ianniello A, Nicoletti S, et al. Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40(6):881–8. https://doi.org/10.1007/s00259-013-2369-z.CrossRefPubMed

65.

Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med. 1998;25(1):79–83.CrossRefPubMed

66.

Belhocine T, Foidart J, Rigo P, Najjar F, Thiry A, Quatresooz P, et al. Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67. Nucl Med Commun. 2002;23(8):727–34.CrossRefPubMed

67.

Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer. 2008;112(11):2447–55. https://doi.org/10.1002/cncr.23469.CrossRefPubMed

68.

Zhang J, Liu Q, Singh A, Schuchardt C, Kulkarni HR, Baum RP. Prognostic value of 18F-FDG PET/CT in a large cohort of patients with advanced metastatic neuroendocrine neoplasms treated with peptide receptor radionuclide therapy. J Nucl Med. 2020;61(11):1560–9. https://doi.org/10.2967/jnumed.119.241414.CrossRefPubMed

69.

Sharma R, Wang WM, Yusuf S, Evans J, Ramaswami R, Wernig F, et al. (68)Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours. Radiother Oncol. 2019;141:108–15. https://doi.org/10.1016/j.radonc.2019.09.003.CrossRefPubMed

70.

Thapa P, Ranade R, Ostwal V, Shrikhande SV, Goel M, Basu S. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor. 2016;37(10):1030–7. https://doi.org/10.1097/mnm.0000000000000547.

71.

Evangelista L, Ravelli I, Bignotto A, Cecchin D, Zucchetta P. Ga-68 DOTA-peptides and F-18 FDG PET/CT in patients with neuroendocrine tumor: A review. Clin Imaging. 2020;67:113–6. https://doi.org/10.1016/j.clinimag.2020.05.035.CrossRefPubMed

72.

Cingarlini S, Ortolani S, Salgarello M, Butturini G, Malpaga A, Malfatti V, et al. Role of Combined 68Ga-DOTATOC and 18F-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors: Implications for Managing Surgical Decisions. Pancreas. 2017;46(1):42–7. https://doi.org/10.1097/mpa.0000000000000745.CrossRefPubMed

73.

Calabrò D, Argalia G, Ambrosini V. Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors. Diagnostics (Basel). 2020;10(12). https://doi.org/10.3390/diagnostics10121059.

74.

Seith F, Schraml C, Reischl G, Nikolaou K, Pfannenberg C, La Fougère C, et al. Fast non-enhanced abdominal examination protocols in PET/MRI for patients with neuroendocrine tumors (NET): comparison to multiphase contrast-enhanced PET/CT. Radiol Med. 2018;123(11):860–70. https://doi.org/10.1007/s11547-018-0917-0.CrossRefPubMed

75.

Cieszanowski A, Lisowska A, Dabrowska M, Korczynski P, Zukowska M, Grudzinski IP, et al. MR Imaging of Pulmonary Nodules: Detection Rate and Accuracy of Size Estimation in Comparison to Computed Tomography. PLoS One. 2016;11(6):e0156272. https://doi.org/10.1371/journal.pone.0156272.CrossRefPubMedPubMedCentral

76.

Beiderwellen KJ, Poeppel TD, Hartung-Knemeyer V, Buchbender C, Kuehl H, Bockisch A, et al. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results. Invest Radiol. 2013;48(5):273–9. https://doi.org/10.1097/RLI.0b013e3182871a7f.CrossRefPubMed

77.

Sawicki LM, Deuschl C, Beiderwellen K, Ruhlmann V, Poeppel TD, Heusch P, et al. Evaluation of (68)Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with (68)Ga-DOTATOC PET/CT. Eur Radiol. 2017;27(10):4091–9. https://doi.org/10.1007/s00330-017-4803-2.CrossRefPubMed

78.

Seith F, Schraml C, Reischl G, Nikolaou K, Pfannenberg C, la Fougere C, et al. Fast non-enhanced abdominal examination protocols in PET/MRI for patients with neuroendocrine tumors (NET): comparison to multiphase contrast-enhanced PET/CT. Radiol Med. 2018;123(11):860–70. https://doi.org/10.1007/s11547-018-0917-0.CrossRefPubMed

79.

Treglia G, Bongiovanni M, Giovanella L. Rare sinonasal small cell neuroendocrine carcinoma evaluated by F-18-FDG PET/MRI. Endocrine. 2014;47(2):654–5. https://doi.org/10.1007/s12020-014-0190-5.CrossRefPubMed

80.

Paola M, De Cobelli F, Picchio M. PET/MRI in Neuroendocrine Tumours: Blessings and Curses. Curr Radiopharm. 2019;12(2):96–7. https://doi.org/10.2174/1874471012999190404151701.CrossRefPubMed

81.

Mayerhoefer ME, Ba-Ssalamah A, Weber M, Mitterhauser M, Eidherr H, Wadsak W, et al. Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomen. Eur Radiol. 2013;23(7):1978–85. https://doi.org/10.1007/s00330-013-2785-2.CrossRefPubMed

82.

Gaertner FC, Beer AJ, Souvatzoglou M, Eiber M, Furst S, Ziegler SI, et al. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors. Invest Radiol. 2013;48(5):263–72. https://doi.org/10.1097/RLI.0b013e31828234d0.CrossRefPubMed

83.

Pirasteh A, Riedl C, Mayerhoefer ME, Giancipoli RG, Larson SM, Bodei L. PET/MRI for neuroendocrine tumors: a match made in heaven or just another hype? Clin Transl Imaging. 2019;7(6):405–13. https://doi.org/10.1007/s40336-019-00344-1.CrossRefPubMedPubMedCentral

84.

Vilanova JC, Barceló J, Smirniotopoulos JG, Pérez-Andrés R, Villalón M, Miró J, et al. Hemangioma from Head to Toe: MR Imaging with Pathologic Correlation. Radiographics. 2004;24(2):367–85. https://doi.org/10.1148/rg.242035079.CrossRefPubMed

85.

Leong S, Kok HK, Delaney H, Feeney J, Lyburn I, Munk P, et al. The Radiologic Diagnosis and Treatment of Typical and Atypical Bone Hemangiomas: Current Status. Can Assoc Radiol J. 2016;67(1):2–11. https://doi.org/10.1016/j.carj.2014.07.002.CrossRefPubMed

86.

Mortelé KJ, Mortelé B, Silverman SG. CT features of the accessory spleen. AJR Am J Roentgenol. 2004;183(6):1653–7. https://doi.org/10.2214/ajr.183.6.01831653.CrossRefPubMed

87.

Freeman JL, Jafri SZ, Roberts JL, Mezwa DG, Shirkhoda A. CT of congenital and acquired abnormalities of the spleen. Radiographics. 1993;13(3):597–610. https://doi.org/10.1148/radiographics.13.3.8316667.CrossRefPubMed

88.

Dodds WJ, Taylor AJ, Erickson SJ, Stewart ET, Lawson TL. Radiologic imaging of splenic anomalies. Am J Roentgenol. 1990;155(4):805–10. https://doi.org/10.2214/ajr.155.4.2119113.CrossRef

89.

Gayer G, Zissin R, Apter S, Atar E, Portnoy O, Itzchak Y. CT findings in congenital anomalies of the spleen. Br J Radiol. 2001;74(884):767–72. https://doi.org/10.1259/bjr.74.884.740767.CrossRefPubMed

90.

Hayward I, Mindelzun RE, Jeffrey RB. Intrapancreatic Accessory Spleen Mimicking Pancreatic Mass on CT. 1992;16(6):984–5. https://doi.org/10.1097/00004728-199211000-00030.CrossRef

91.

Zeman M, Zembala-Nożyńska E, Sczasny J, Strączyński M, Wideł M. Intrapancreatic accessory spleen imitating a pancreatic neoplasm. Pol Przegl Chir. 2011;83(10):568–70. https://doi.org/10.2478/v10035-011-0090-9.CrossRefPubMed

92.

Meyer T, Maier M, Höller S, Fein M. Intrapancreatic accessory spleen: a differential diagnosis of pancreatic tumour. Zentralbl Chir. 2007;132(1):73–6. https://doi.org/10.1055/s-2007-960480.CrossRefPubMed

93.

Uchiyama S, Chijiiwa K, Hiyoshi M, Ohuchida J, Imamura N, Nagano M, et al. Intrapancreatic accessory spleen mimicking endocrine tumor of the pancreas: case report and review of the literature. J Gastrointest Surg. 2008;12(8):1471–3. https://doi.org/10.1007/s11605-007-0325-6.CrossRefPubMed

94.

Sandström M, Velikyan I, Garske-Román U, Sörensen J, Eriksson B, Granberg D, et al. Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors. J Nucl Med. 2013;54(10):1755–9. https://doi.org/10.2967/jnumed.113.120600.CrossRefPubMed

95.

Bostancı EB, Oter V, Okten S, Küçük NO, Soydal C, Turhan N, et al. Intra-pancreatic Accessory Spleen Mimicking Pancreatic Neuroendocrine Tumor on 68-Ga-Dotatate PET/CT. Arch Iran Med. 2016;19(11):816–9.PubMed

96.

Lancellotti F, Sacco L, Cerasari S, Bellato V, Cicconi S, Ciardi A, et al. Intrapancreatic accessory spleen false positive to 68Ga-Dotatoc: case report and literature review. World J Surg Oncol. 2019;17(1):117. https://doi.org/10.1186/s12957-019-1660-2.CrossRefPubMedPubMedCentral

97.

Royal HD, Brown ML, Drum DE, Nagle CE, Sylvester JM, Ziessman HA. Procedure guideline for hepatic and splenic imaging. Society of Nuclear Medicine. J Nucl Med. 1998;39(6):1114–6.

98.

Toth GB, Varallyay CG, Horvath A, Bashir MR, Choyke PL, Daldrup-Link HE, et al. Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. Kidney Int. 2017;92(1):47–66. https://doi.org/10.1016/j.kint.2016.12.037.CrossRefPubMedPubMedCentral

99.

Bashir MR, Bhatti L, Marin D, Nelson RC. Emerging applications for ferumoxytol as a contrast agent in MRI. J Magn Reson Imaging. 2015;41(4):884–98. https://doi.org/10.1002/jmri.24691.CrossRefPubMed

100.

Wang YX, Idee JM. A comprehensive literatures update of clinical researches of superparamagnetic resonance iron oxide nanoparticles for magnetic resonance imaging. Quant Imaging Med Surg. 2017;7(1):88–122. https://doi.org/10.21037/qims.2017.02.09.CrossRefPubMedPubMedCentral

101.

Harisinghani MG, Saini S, Weissleder R, Rubin D, deLange E, Harms S, et al. Splenic imaging with ultrasmall superparamagnetic iron oxide ferumoxtran-10 (AMI-7227): preliminary observations. J Comput Assist Tomogr. 2001;25(5):770–6. https://doi.org/10.1097/00004728-200109000-00017.CrossRefPubMed

102.

Ivanidze J, Roytman M, Lin E, Magge RS, Pisapia DJ, Liechty B, et al. Gallium-68 DOTATATE PET in the Evaluation of Intracranial Meningiomas. J Neuroimaging. 2019;29(5):650–6. https://doi.org/10.1111/jon.12632.CrossRefPubMed

103.

Klinaki I, Al-Nahhas A, Soneji N, Win Z. 68Ga DOTATATE PET/CT uptake in spinal lesions and MRI correlation on a patient with neuroendocrine tumor: potential pitfalls. Clin Nucl Med. 2013;38(12):e449–53. https://doi.org/10.1097/RLU.0b013e31827a2325.CrossRefPubMed

104.

Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015;35(2):500–16. https://doi.org/10.1148/rg.352140164.CrossRefPubMed

105.

Cleary JO, Yeung J, McMeekin H, Wilhelm T, Wagner T. The significance of incidental brain uptake on 68Ga-DOTATATE PET-CT in neuroendocrine tumour patients. Nucl Med Commun. 2016;37(11):1197–205. https://doi.org/10.1097/MNM.0000000000000571.CrossRefPubMed

106.

Law WP, Fiumara F, Fong W, Macfarlane DJ. The “double pituitary hot spot” sign of skull base meningioma on gallium-68-labelled somatostatin analogue PET. J Med Imaging Radiat Oncol. 2013;57(6):680–3. https://doi.org/10.1111/1754-9485.12069.CrossRefPubMed

107.

Delle Fave G, O’Toole D, Sundin A, Taal B, Ferolla P, Ramage JK, et al. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. Neuroendocrinology. 2016;103(2):119–24. https://doi.org/10.1159/000443168.CrossRefPubMed

108.

Niederle B, Pape UF, Costa F, Gross D, Kelestimur F, Knigge U, et al. ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum. Neuroendocrinology. 2016;103(2):125–38. https://doi.org/10.1159/000443170.CrossRefPubMed

109.

O’Toole D, Kianmanesh R, Caplin M. ENETS 2016 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: An Update. Neuroendocrinology. 2016;103(2):117–8. https://doi.org/10.1159/000443169.CrossRefPubMed

110.

Pavel M, O’Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology. 2016;103(2):172–85. https://doi.org/10.1159/000443167.CrossRefPubMed

111.

Ramage JK, De Herder WW, Delle Fave G, Ferolla P, Ferone D, Ito T, et al. ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms. Neuroendocrinology. 2016;103(2):139–43. https://doi.org/10.1159/000443166.CrossRefPubMed

112.

De Mestier L, Dromain C, D’Assignies G, Scoazec J-Y, Lassau N, Lebtahi R, et al. Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art. Endocr Relat Cancer. 2014;21(3):R105–20. https://doi.org/10.1530/erc-13-0365.CrossRefPubMed

113.

Castaño JP, Sundin A, Maecke HR, Villabona C, Vazquez-Albertino R, Navarro E, et al. Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges. Cancer Metastasis Rev. 2014;33(1):353–9. https://doi.org/10.1007/s10555-013-9465-1.CrossRefPubMed

114.

Bodei L, Sundin A, Kidd M, Prasad V, Modlin IM. The Status of Neuroendocrine Tumor Imaging: From Darkness to Light? Neuroendocrinology. 2014;101(1):1–17. https://doi.org/10.1159/000367850.CrossRefPubMed

Titel: Imaging of neuroendocrine tumors: A pictorial review of the clinical value of different imaging modalities
verfasst von: Ali Pirasteh
Petra Lovrec
Lisa Bodei
Publikationsdatum: 30.03.2021
Verlag: Springer US
Erschienen in: Reviews in Endocrine and Metabolic Disorders / Ausgabe 3/2021
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-021-09631-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Imaging of neuroendocrine tumors: A pictorial review of the clinical value of different imaging modalities

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

Evaluating cost-effectiveness in the management of neuroendocrine neoplasms

Foreword to the special issue on advances in neuroendocrine neoplasms

Are recist criteria adequate in assessing the response to therapy in metastatic NEN?

Chemotherapy in NEN: still has a role?

Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer

Classification of neuroendocrine neoplasms: lights and shadows

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin